Eli Lilly (LLY) Current Assets (2009 - 2026)

Eli Lilly has reported Current Assets for 18 years, with the latest figure at $54.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 32.9% year-over-year to $54.8 billion; the trailing twelve-month figure through Mar 2026 stood at $54.8 billion (up 32.9% YoY), and the FY2025 full-year result was $55.6 billion, up 69.91% from the prior year.
• Current Assets for Q1 2026 stood at $54.8 billion, down from $55.6 billion in the prior quarter.
• The five-year high for Current Assets was $62.1 billion in Q3 2025, with the low at $17.0 billion in Q1 2022.
• Historically, Current Assets has averaged $32.0 billion across 5 years, with a median of $25.7 billion in 2023.
• Annual changes were most pronounced in 2022 — Current Assets fell 2.26% — and 2025, when it jumped 97.58%.
• Eli Lilly's Current Assets stood at $18.0 billion in 2022, then jumped by 42.65% to $25.7 billion in 2023, then rose by 27.26% to $32.7 billion in 2024, then soared by 69.91% to $55.6 billion in 2025, then declined by 1.43% to $54.8 billion in 2026.
• The last three Current Assets figures came in at $54.8 billion (Q1 2026), $55.6 billion (Q4 2025), and $62.1 billion (Q3 2025), per Business Quant data.